Postherpetic Neuralgia (PHN)

EFFICACY IN PHN
In an 8-week pivotal study, LYRICA (pregabalin) provided powerful relief in PHN1,2
*LYRICA 300 mg/day and 600 mg/day, divided TID.
Baseline observation carried forward (BOCF) analysis of intent-to-treat population.
Patients with low creatinine clearance (>30 and ≤60 mL/min; n=30) received a maximum dosage of LYRICA 300 mg/day, but were analyzed with the 600 mg/day group having normal creatinine clearance (>60 mL/min; n=59).
Study description
In the same 8-week pivotal study, LYRICA cut PHN pain in half1,2*
LYRICA 300 mg/day and 600 mg/day, divided TID.
Baseline observation carried forward (BOCF) analysis of intent-to-treat population.
Patients with low creatinine clearance (>30 and ≤60 mL/min; n=30) received a maximum dosage of LYRICA 300 mg/day, but were analyzed with the 600 mg/day group having normal creatinine clearance (>60 mL/min; n=59).
*Over 1.5x more patients on LYRICA achieved a PHN pain reduction of 50% or more vs those on placebo1,2
Study description
DOSING IN PHN
Consider your next steps for LYRICA titration, based on efficacy and tolerability
Dosage may be increased to 300 mg/day based on efficacy and tolerability within 1 week
Patients may be titrated to 600 mg/day if they are not experiencing sufficient pain relief after 2 to 4 weeks of treatment with 300 mg/day
When discontinuing LYRICA, taper gradually over a minimum of 1 week
Adjust the LYRICA daily dose based on renal function
SAFETY IN PHN
In controlled trials in adults with PHN,
Adverse reactions were generally mild to moderate1
LYRICA was administered in doses divided BID or TID.
*Includes all doses of LYRICA that were studied in PHN (eg, 75 mg/day).
Reactions in ≥5% of all LYRICA-treated patients and occurring at least twice the rate of placebo.
In LYRICA clinical trials of postherpetic neuralgia, 14% of LYRICA-treated patients and 7% of placebo-treated patients discontinued due to adverse reactions.
Clinical Background
With the Co-Pay Savings Card, eligible patients pay as little as $4 per Rx for branded LYRICA
*Includes patients who received any study dose of LYRICA in placebo-controlled studies of fibromyalgia, painful diabetic peripheral neuropathy, postherpetic neuralgia, and neuropathic pain associated with spinal cord injury, as well as open-label extensions of those studies.
References: 1. Data on file. Pfizer Inc, New York, NY. 2. Dworkin RH, Corbin AE, Young JP Jr, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2003;60(8):1274-1283.
*TERMS AND CONDITIONS
Offer Terms & Conditions:
By using the Co-Pay Savings Card, you acknowledge that you currently meet the eligibility criteria and will comply with the following terms and conditions:
Patients are not eligible to use this card or participate in this program if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veteran Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”). Patient must have private insurance. Offer is not valid for cash paying patients. The value of this card is limited to $175 per month per prescription (“offering period”) or the amount of your co-pay, whichever is less (Maximum annual savings of $2100). This program is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plan or other private health or pharmacy benefit programs. You must deduct the value received under this program from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf. You are responsible for reporting use of this program to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the program, as may be required. You should not use the program if your insurer or health plan prohibits use of manufacturer co-pay cards. You must be 18 years of age or older to accept this offer. This offer is not valid where prohibited by law.
For Massachusetts residents:
This co-pay offer is not valid if an A/B generic is available for Massachusetts residents whose prescriptions are covered in whole or in part by third-party insurance.
For California residents:
This co-pay offer is not valid if a generic is available for California residents whose prescriptions are covered in whole or in part by third-party insurance.
Please check with your healthcare professional or insurer to confirm eligibility. This offer cannot be combined with any other savings, free trial or similar offer for the specified prescription. The co-pay card will be accepted only at participating pharmacies. The co-pay card is not health insurance. Offer good only in the U.S. and Puerto Rico. The co-pay card is limited to one per person during this offering period and is not transferable. A co-pay card may not be redeemed more than once per offering period per patient. No other purchase is necessary. Data related to your redemption of the co-pay card may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other co-pay card redemptions and will not identify you. Pfizer reserves the right to rescind, revoke or amend this offer without notice. No membership fee. For more information, visit our website www.lyrica.com, call
1-866-954-1475,
or contact us at 2250 Perimeter Park Drive, Suite 300, Morrisville, NC 27560.
Offer expires 12/31/2020.
For reimbursement when using a nonparticipating pharmacy/mail order:
Pay for prescription, and mail copy of original pharmacy receipt (cash register receipt NOT valid) with product name, date, and amount circled to: Co-Pay Savings Card, 2250 Perimeter Park Drive, Suite 300, Morrisville, NC 27560. Be sure to include a copy of the front of your activated Co-Pay Savings Card, your name and mailing address.